Effects and Underlying Mechanism of Lipid Lowering Intervention on Vascular Protection in Hypertensive Patients

• Status: Unknown status
• Trial end date: 2016-10-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of EMINENT study is to evaluate the efficacy of Xuezhikang or atorvastatin in hypertensive patients at low/moderate cardiovascular risk.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Chinese Academy of Medical Sciences, Fuwai Hospital
• Collaborators: Beijing Hospital of Traditional Chinese Medicine; Peking Union Medical College Hospital; Peking University First Hospital
• Treatments: Atorvastatin; Atorvastatin Calcium

Criteria

Inclusion Criteria:

• All patients must meet the hypertension with low or moderate cardiovascular risk following 2010 Guidelines for prevention and treatment of hypertension in China

Exclusion Criteria:

• Secondary Hypertension

• Women who are pregnant or lactating

• History of mental instability, or major psychiatric illness not adequately controlled and stable on therapy

• Type 2 Diabetes

• Active liver disease or impaired liver function tests

• Impaired renal function

• Uncontrolled cardiac arrhythmia

• Patient who is unable to give informed consent

• Any condition or situation, which in the opinion of the investigator, might pose a risk to the patient or confound the results of the study